I-MAB (IMAB) Marketable Securities : $20.06 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. I-MAB's Marketable Securities for the quarter that ended in Dec. 2023 was $20.06 Mil.

I-MAB's annual Marketable Securities declined from Dec. 2021 ($118.25 Mil) to Dec. 2022 ($33.77 Mil) and declined from Dec. 2022 ($33.77 Mil) to Dec. 2023 ($20.06 Mil).

I-MAB Marketable Securities Historical Data

The historical data trend for I-MAB's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Marketable Securities Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Marketable Securities

Get a 7-Day Free Trial

4.56

4.82

118.25

33.77

20.06

I-MAB Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Marketable Securities	Get a 7-Day Free Trial								118.25	31.54	33.77	81.82	20.06

I-MAB Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

I-MAB (NAS:IMAB) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

I-MAB Marketable Securities Related Terms

Thank you for viewing the detailed overview of I-MAB's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB (IMAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

0VY:Germany

Address

555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124

Website

https://www.i-mabbiopharma.com

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.